文献速递肾小球疾病

狼疮性肾炎初始治疗的系统评价与网络Meta分析

Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis.
PubMed 文献 · Kidney Int Rep · 2025-07-03

该系统评价与网络Meta分析纳入40项随机对照试验共5450例患者、16种干预,比较活动性狼疮性肾炎初始治疗。与单用麦考酚酸类似物相比,伏环孢素联合麦考酚酸类似物、贝利尤单抗联合麦考酚酸类似物及奥妥珠单抗联合麦考酚酸类似物提高完全肾脏缓解率,证据确定性分别为高、高、中。

要点

  • 伏环孢素联合麦考酚酸类似物较单用麦考酚酸类似物提高完全肾脏缓解率,证据确定性高。
  • 贝利尤单抗联合麦考酚酸类似物较单用麦考酚酸类似物提高完全肾脏缓解率,证据确定性高。
  • 奥妥珠单抗联合麦考酚酸类似物较单用麦考酚酸类似物提高完全肾脏缓解率,证据确定性中等。

核心结论

  • 联合治疗,尤其是伏环孢素、贝利尤单抗或奥妥珠单抗联合麦考酚酸类似物,为狼疮性肾炎初始治疗提供更优结局。
  • 鉴于狼疮性肾炎的复杂性,临床医生应结合药物可及性、费用和患者个体偏好权衡这些发现以指导治疗决策。

研究设计与样本

  • 系统评价与网络Meta分析,检索多个数据库自建库至2025年2月,纳入比较狼疮性肾炎初始治疗的随机对照试验。
  • 共纳入40项随机对照试验、5450例患者、16种干预(12种药物单用或联合使用)。
  • 采用频率学派随机效应网络Meta分析,以限制性最大似然法估计异质性,并采用GRADE方法评估证据确定性。

主要发现

  • 与单用麦考酚酸类似物相比,伏环孢素联合麦考酚酸类似物提高完全肾脏缓解率(风险差:每1000例多281.38例,95%CI:多146.26至多456.42;证据确定性高)。
  • 与单用麦考酚酸类似物相比,贝利尤单抗联合麦考酚酸类似物提高完全肾脏缓解率(风险差:每1000例多145.02例,95%CI:多72.73至多230.92;证据确定性高)。
  • 与单用麦考酚酸类似物相比,奥妥珠单抗联合麦考酚酸类似物提高完全肾脏缓解率(风险差:每1000例多134.23例,95%CI:多30.37至多269.68;证据确定性中等)。
  • 与单用麦考酚酸类似物相比,他克莫司联合麦考酚酸类似物也显示潜在获益(风险差:每1000例多113.69例,95%CI:多25.23至多217.7;证据确定性低)。

临床怎么用

  • 临床医生应结合药物可及性、费用和患者个体偏好,权衡联合治疗(伏环孢素、贝利尤单抗或奥妥珠单抗联合麦考酚酸类似物)的获益以指导狼疮性肾炎初始治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: This study aimed to evaluate the comparative efficacy and safety of various initial treatments for active lupus nephritis (LN) through a systematic review and network meta-analysis (NMA). METHODS: We conducted a comprehensive literature search across multiple databases from inception to February 2025 to identify randomized controlled trials (RCTs) comparing initial treatments for LN. We performed a frequentist random-effects NMA using the restricted maximum likelihood method to estimate heterogeneity. We used the GRADE approach to assess the certainty of evidence. RESULTS: We included 40 RCTs encompassing 5450 patients and 16 interventions (12 drugs administered alone or in combination). Mycophenolic acid analogs (MPAAs) were selected as the common comparator. The network meta-analysis revealed that voclosporin (VCS) combined with MPAA (risk difference [RD]: 281.38 more/1000, 95% confidence interval [CI]: 146.26 more to 456.42 more; high certainty), belimumab (BEL) combined with MPAA (RD: 145.02 more/1000, 95% CI: 72.73 more to 230.92 more; high certainty), and obinutuzumab (OBI) combined with MPAA (RD: 134.23 more/1000, 95% CI: 30.37 more to 269.68 more; moderate certainty) increased complete renal response (CRR) compared with MPAA alone. Tacrolimus (TAC) combined with MPAA (RD: 113.69 more/1000, 95% CI: 25.23 more to 217.7 more; low certainty) also showed potential benefits but with low certainty evidence. CONCLUSION: Combination therapies, particularly VCS, BEL, or OBI with MPAA, provide enhanced outcomes for LN initial treatment. Given the complexity of LN, clinicians should weigh these findings alongside considerations such as drug availability, cost, and individual patient preferences to guide treatment decisions.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Izcovich A, Tortosa F, Bengolea A, et al. Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis. Kidney Int Rep. 2025. PMID: 40980661. doi:10.1016/j.ekir.2025.06.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。